Find a Therapist at

Find a Local Therapist for In-Person or Telehealth Therapy

  for Consumers
Find a Therapist
Find a Treatment Center
Telehealth Therapists
About Therapy
Featured Articles
Support Groups
National Hotlines
What's New
  for Providers
List Your Practice
List Your Treatment Center
Custom Web Design
Publish an Article
My Account

Breakthrough Therapies: FDA Approval of Ketamine Nasal Spray "Spravato" and MDMA Capsules Paves the Way for Psychedelic-Assisted Therapy

» Mental Health Library » Disorders & Conditions » Major Depressive Disorder » Featured Article

By: Adam Greenberg, LCSW

Adam Greenberg, LCSW

In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved two groundbreaking treatments for mental health disorders: Ketamine Nasal Spray, known commercially as "Spravato," and MDMA (3,4-methylenedioxymethamphetamine) capsules. These approvals mark a significant shift in the approach to mental health treatment, opening the door to psychedelic-assisted therapy as a viable option for patients suffering from conditions such as depression and post-traumatic stress disorder (PTSD).

Spravato: A Breakthrough in Ketamine Therapy

Spravato, developed by Janssen Pharmaceuticals, is a nasal spray formulation of esketamine, a derivative of the dissociative anesthetic ketamine. Ketamine has long been recognized for its rapid antidepressant effects, and Spravato offers a more convenient and controlled delivery method compared to traditional ketamine infusions.

The FDA approval of Spravato for treatment-resistant depression in adults who have not responded to other treatments represents a paradigm shift in psychiatric care. Studies have shown that Spravato can lead to significant improvements in depressive symptoms within hours or days, compared to the weeks or months required for conventional antidepressants to take effect. This rapid onset of action offers hope to patients grappling with severe depression and suicidal ideation, providing a potentially life-saving intervention.

Moreover, Spravato's approval underscores the importance of innovation in psychiatric pharmacotherapy. By targeting the glutamate system, rather than the monoamine neurotransmitters targeted by traditional antidepressants, ketamine and its derivatives offer a novel mechanism of action that holds promise for individuals resistant to conventional treatments.

MDMA-Assisted Therapy: A Breakthrough in PTSD Treatment

In addition to Spravato, the FDA has also granted breakthrough therapy designation to MDMA for the treatment of PTSD. Developed by the Multidisciplinary Association for Psychedelic Studies (MAPS), MDMA-assisted therapy involves the administration of MDMA in conjunction with psychotherapy sessions. MDMA, often referred to as ecstasy or molly, is a synthetic compound known for its empathogenic and entactogenic effects.

Clinical trials have demonstrated the potential of MDMA-assisted therapy to effectively reduce symptoms of PTSD, including intrusive thoughts, hyperarousal, and avoidance behaviors. By enhancing feelings of trust, empathy, and emotional openness, MDMA may facilitate deeper therapeutic insights and help patients process traumatic experiences in a supportive environment.

The FDA's recognition of MDMA as a breakthrough therapy underscores the urgent need for innovative approaches to addressing the debilitating symptoms of PTSD, particularly in populations for whom existing treatments have proven inadequate. With an estimated 8 million adults in the United States living with PTSD, the approval of MDMA-assisted therapy offers a ray of hope for those struggling to reclaim their lives from the grip of trauma.

Exploring the Potential of Psychedelic-Assisted Therapy

The approvals of Spravato and MDMA represent just the tip of the iceberg in the burgeoning field of psychedelic-assisted therapy. Researchers are increasingly turning their attention to other psychedelics, such as psilocybin (the active compound in magic mushrooms), LSD, and ayahuasca, for their therapeutic potential in treating a wide range of mental health conditions.

Preliminary studies have shown promising results for psychedelics in the treatment of depression, anxiety, addiction, and end-of-life distress. By modulating brain networks involved in mood regulation, cognition, and self-awareness, psychedelics may offer profound therapeutic benefits beyond the scope of conventional treatments.

However, it's essential to proceed with caution and rigorously evaluate the safety and efficacy of these substances through well-designed clinical trials. The renaissance of psychedelic research represents a unique opportunity to revolutionize mental health care, but it also requires responsible stewardship to ensure patient safety and optimize treatment outcomes.

In conclusion, the FDA approvals of Spravato and MDMA capsules mark a historic milestone in the advancement of psychedelic-assisted therapy. These breakthrough treatments offer hope to millions of individuals grappling with treatment-resistant depression and PTSD, providing new avenues for healing and recovery. As we continue to explore the therapeutic potential of psychedelics, we must remain committed to rigorous scientific inquiry and ethical practice to realize the full promise of this paradigm-shifting approach to mental health care.


  1. Daly, M. (2021). FDA Approves Spravato Nasal Spray for MDD Treatment. Psychiatry Advisor. Link

  2. Multidisciplinary Association for Psychedelic Studies (MAPS). (2022). MDMA-Assisted Therapy. Link

  3. Janssen Pharmaceuticals. (2020). FDA Approves SPRAVATO™ (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior. Link

  4. Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., ... & de Araujo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological medicine, 49(4), 655-663.

About the Author...

Mr. Greenberg is dedicated to his clients' well-being, guiding them through life's challenges, including anxiety, depression, communication issues, couple conflicts, and more. He offers a variety of coping strategies and emotional support.

What sets him apart from other therapists, is his ability to implement humor into therapy, promoting a positive perspective on adversity. With a passion for helping others, his diverse career experiences enable him to connect with individuals from various backgrounds.

Mr. Greenberg graduated with honors from Fordham University Graduate School of Social Services. Prior to pursuing a career as a therapist, he accumulated a wealth of experience through working in over 15 diverse jobs spanning 4-5 distinct careers. This journey, complemented by extensive travel and cultural immersion, has uniquely shaped Mr. Greenberg, enabling him to connect with individuals from a wide array of ethnic and cultural backgrounds.

Click here to contact or learn more about Adam Greenberg

Last Update: 4/10/2024

Home  |  Provider Directory  |  Mental Health Library  |  Resource Center  |  For Providers
Find a Therapist  |  Find a Treatment Center  |  List Your Practice  |  List Your Treatment Center
About Us  |  Contact Us  |  User Agreement  |  Privacy Policy  |  Site Map
The information provided on this site is for educational or informational purposes only and should not be treated as medical or behavioral health care advice. The information is not intended to be used for medical diagnosis or treatment or as a substitute for consultation with a qualified health care provider. Please consult your health care provider if you have any questions or concerns about your health.
© 2024, Inc. All rights reserved.
Welcome Guestbook What's New Site Map Find a Therapist Find a Treatment Center About Therapy Frequently Asked Questions Disorders & Conditions Medications Treatment Approaches Featured Articles News Archive Mental Health Dictionary Support Groups National Hotlines Mental Health Books Related Web Sites For Providers Provider Login Back to top of page